• LAST PRICE
    3.1413
  • TODAY'S CHANGE (%)
    Trending Down-0.2987 (-8.6831%)
  • Bid / Lots
    2.6000/ 10
  • Ask / Lots
    3.4300/ 4
  • Open / Previous Close
    3.5300 / 3.4400
  • Day Range
    Low 3.1413
    High 3.5300
  • 52 Week Range
    Low 2.5200
    High 20.9100
  • Volume
    5,380
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.44
TimeVolumeELYM
09:32 ET2453.53
09:34 ET6003.4103
09:43 ET1003.43
09:50 ET1003.34
11:00 ET1003.275
11:15 ET1003.27
11:18 ET16023.25
01:21 ET1003.43
01:39 ET1003.27
03:52 ET3003.1413
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesELYM
Eliem Therapeutics Inc
83.5M
-1.5x
---
United StatesAURX
Nuo Therapeutics Inc
83.6M
-32.2x
---
United StatesRPHM
Reneo Pharmaceuticals Inc
83.2M
-1.7x
---
United StatesIMUC
ImmunoCellular Therapeutics Ltd
83.8M
-17.0x
---
United StatesMGTA
Magenta Therapeutics Inc
83.0M
-1.1x
---
United StatesNXTC
NextCure Inc
82.4M
-1.1x
---
As of 2022-09-25

Company Information

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company. The Company focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The Company offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The Company provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.

Contact Information

Headquarters
23515 NE NOVELTY HILL ROAD SUITE B221 #125REDMOND, WA, United States 98053
Phone
425-276-2300
Fax
302-636-5454

Executives

Independent Chairman of the Board
Andrew Levin
President, Chief Executive Officer, Director
Robert Azelby
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Erin Lavelle
Executive Vice President - Research and Development, Chief Scientific Officer
Valerie Morisset
Executive Vice President, General Counsel
James Bucher

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$83.5M
Revenue (TTM)
$0.00
Shares Outstanding
26.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.16
Book Value
$6.37
P/E Ratio
-1.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.